
Types of Cartilage Damage: What Regenerative Options Exist for Each?
9 min readFocal cartilage defects, osteochondritis dissecans, osteoarthritis and meniscus tears need different evidence. Where MACI is approved and where MSCs remain experimental.
An independent reference library on stem cell therapy and cancer immunotherapy research.
471 articles · 2 topics · 351 Stem Cell Research · 120 Cancer Immunotherapy
Step 1 — Topic
Step 2 — Category
All 471 articles

Focal cartilage defects, osteochondritis dissecans, osteoarthritis and meniscus tears need different evidence. Where MACI is approved and where MSCs remain experimental.

Exercise activates muscle satellite cells and temporarily mobilizes blood progenitors. What human and animal studies show—and what they cannot yet prove about regeneration.

Rheumatoid arthritis symptoms, diagnosis and proven DMARD treatments explained, with a look at why MSC therapy remains an early-stage research question.

Epidermolysis bullosa causes skin to blister from minor friction. What bone marrow transplant and MSC infusion trials — including the 2025 MissionEB phase 3 study — actually show for severe recessive dystrophic EB.

Injecting MSCs into radiation-damaged salivary glands showed early promise — but the 120-patient MESRIX-III placebo-controlled trial did not confirm a significant benefit. What the evidence really says.

IV infusion, local injection, and surgical implantation send stem cells to very different places. How each delivery route works, what it's used for, and why the lungs trap most IV-infused cells.

All 38 patients in a Phase 1 trial of the BCMA CAR-T anito-cel responded, with nearly 80% in complete response and no delayed neurotoxicity — encouraging, but still early, single-arm evidence.

Before CAR-T cells can be engineered, a patient's T cells must be collected by leukapheresis — a several-hour blood-filtering procedure whose success is not guaranteed in heavily pretreated patients.

Small human studies of adipose-derived and placental stem cells show shrinking plaques and less distress in Peyronie's disease, but the best trial missed its curvature goal and nothing is FDA-approved.

Lab studies and a small case series suggest mesenchymal stem cells may calm hidradenitis suppurativa inflammation and help stubborn tunnels heal — but the approach is experimental and not FDA-approved.

Stem cell therapies move through a funding relay — NIH and state grants, universities, foundations, then venture capital. Legitimate trials don't charge patients for the experimental product.

The FDA's 2024 class-wide boxed warning on secondary T-cell cancers after CAR-T flagged a real signal — but the largest datasets since show the absolute risk is low and CAR-T's benefits still outweigh it.
Every feature article on regenmedreview carries a Sources block listing its references. Where the original source material included no external citations, that is stated explicitly rather than left blank.